Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2353-2357

  Chin, Kin Fah ^a   Greenman, John ^a   Reusch, Petra ^b   Gardiner, Eric ^a   Marme, Dieter ^b   Monson, John R T ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Colorectal cancer; Tumour marker

Indexed keywords

ANGIOPOIETIN RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER METASTASIS; PERITONEUM METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SERUM; TUMOR GROWTH;

COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, TIE-2; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 4444332836     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Folkman J: Angiogenesis research: from laboratory to clinic. Forum (Genova) 9: 3 Suppl 3: 59-62, 1999.
2. Senger DR: Molecular framework for angiogenesis. Am J Pathol 149: 1-8, 1996.
3. Plate KH, Breier G, Weich HA, Mennel HD and Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo mechanisms. Int J Cancer 15: 520-9, 1994.
4. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD and Sessa WC: Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79(2): 213-223, 1999.
5. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423): 841-844, 1993.
6. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA and Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95(15): 8795-800, 1998.
7. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
8. Ferrara N, Gerber H and LeCouter J: The biology of VEGF and its receptors. Nature Medicine 9(6): 669-676, 2003.
9. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
10. Kendall RL and Thomas KA: Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
11. Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996.
12. Park JE, Chen HH, Winer J, Houck KA and Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654, 1994.
13. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J and Breitman ML: Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7: 1471-1480, 1992.
14. Korhonen J, Polvi A, Partanen J and Alitalo K: The mouse Tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. Oncogene 9: 395-403, 1994.
15. Batard P, Sansilvestri P, Scheinecker C, Knapp W, Debili N, Vainchenker W, Buhring HJ, Monier MN, Kukk E, Partanen J, Matikainen MT, Alitalo R, Hatzfeld J and Alitalo K: The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. Blood 87: 2212-2220, 1996.
16. Hashiyama M, Iwama A, Ohshiro K, Kurozumi K, Yasunaga K, Shimizu Y, Masuho Y, Matsuda I, Yamaguchi N and Suda T: Predominant expression of a receptor tyrosine kinase, Tie, in hematopoietic stem cells and B cells. Blood 87: 93-101, 1996.
17. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A and Breitman ML: Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 16: 1897-1909, 1994.
18. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W and Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 6535: 70-74, 1996.
19. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS and Peters KG: Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81: 567-574, 1997.
20. Koblizek TI, Runting AS, Stacker SA, Wilks AF, Risau W and Deutsch U: Tie2 receptor expression and phosphorylation in cultured cells and mouse tissues. Eur J Biochem 244: 774-779, 1997.
21. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A and Strawn LM: Dominant-negative inhibition of FLK-1 suppresses the growth of many tumour types in vivo. Cancer Res 56(7): 1615-1620, 1996.
22. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D and Martiny-Baron G: Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59(13): 3185-91, 1999.
23. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, Kotake Y and Konishi Y: Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5: 9: 2506-2510, 1999.
24. Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S and Alitalo K: Enhanced expression of the Tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 54(24): 6571-6577, 1994.
25. Salven P, Joensuu H, Heikkila P, Matikainen MT, Wasenius VM, Alanko A and Alitalo K: Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74(1): 69-72, 1996.
26. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME and Li LY: Angiopoietin-1 and its receptor tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 58(3): 224-37, 1999.
27. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS and Peters K: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100(8): 2072-8, 1997.
28. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ and Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9(1): 49-58, 1998.
29. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorrin-Rivas MJ, Furumoto K, Kaneda Y and Imamura M: Soluble flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 7(12): 1027-33, 2000.
30. Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H and Hara N: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 15; 60(8): 2169-77, 2000.
31. Crystal RG: In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol 43 Suppl: S90-9, 1999.
32. Procopio WN, Pelavin PI, Lee WM and Yeilding NM: Angiopoietin-1 and -2 coiled coil domains mediate distinct homooligomerization patterns, but fibrinogen-like domains mediate ligand activity. J Biol Chem 274(42): 30196-30201, 1999.
33. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD and Isner JM: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83(3): 233-240, 1998.
34. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322): 55-60, 1997.
35. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S and Trogan E: Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 77(1): 51-56, 1998.